Market Place
Sourcing Support
FDA Issues Form 483 to Aurobindo Pharma Limited, Unit VII
20 Feb 2026 //
FDA
FDA Issues Form 483 to Aurobindo Pharma
03 Oct 2025 //
FDA
FDA Issues Form 483 to Aurobindo Pharmaceuticals
05 Sep 2025 //
FDA
Enforcement Report - Week of June 25, 2025
25 Jun 2025 //
FDA
Enforcement Report - Week of January 1, 2025
01 Jan 2025 //
FDA
Enforcement Report - Week of December 25, 2024
25 Dec 2024 //
FDA
FDA Issues Form 483 to Apitoria Pharma Private Ltd.
07 Oct 2024 //
FDA
Aurobindo Pharma`s Generic Lacosamide Receives Approval in the U.S.
24 Jan 2024 //
FDA
Enforcement Report - Week of September 27, 2023
27 Sep 2023 //
FDA
Enforcement Report - Week of May 31, 2023
31 May 2023 //
FDA
Enforcement Report - Week of May 17, 2023
17 May 2023 //
FDA
Enforcement Report - Week of January 11, 2023
11 Jan 2023 //
FDA
Aurobindo Pharma Unit 9 on FDA Import Alert List
07 Dec 2022 //
FDA
FDA Issues Form 483 Aurobindo Pharma Unit 9
07 Dec 2022 //
FDA
Enforcement Report - Week of November 2, 2022
02 Nov 2022 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Limited
14 Sep 2022 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Ltd.
25 May 2022 //
FDA
Enforcement Report - Week of April 20, 2022
20 Apr 2022 //
FDA
Enforcement Report - Week of February 23, 2022
23 Feb 2022 //
FDA
Enforcement Report - Week of February 2, 2022
02 Feb 2022 //
FDA
Aurobindo Pharmaceutical Limited Receives FDA Warning Letter
26 Jan 2022 //
FDA
Aurobindo Pharma Limited on Health Canada Inspection List
08 Jan 2022 //
HEALTH CANADA
Enforcement Report - Week of September 29, 2021
29 Sep 2021 //
FDA
Enforcement Report - Week of August 18, 2021
18 Aug 2021 //
FDA
FDA issues Form 483 to Aurobindo Pharma
12 Aug 2021 //
FDA
Enforcement Report - Week of March 10, 2021
10 Mar 2021 //
FDA
Aurolife Pharma Receives FDA Warning Letter
25 Nov 2020 //
FDA
Enforcement Report - Week of September 2, 2020
02 Sep 2020 //
FDA
Enforcement Report - Week of July 1, 2020
01 Jul 2020 //
FDA
Enforcement Report - Week of April 22, 2020
22 Apr 2020 //
FDA
Enforcement Report - Week of December 4, 2019
04 Dec 2019 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Ltd. Unit 5
21 Nov 2019 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Ltd. Unit 8
21 Nov 2019 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Unit 4
14 Nov 2019 //
FDA
Enforcement Report - Week of October 23, 2019
24 Oct 2019 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Ltd.
10 Oct 2019 //
FDA
Enforcement Report - Week of September 4, 2019
04 Sep 2019 //
FDA
Aurobindo Pharma Limited Receives FDA Warning Letter
03 Jul 2019 //
FDA
Aurobindo Pharma Ltd. Telangana Receives FDA Form 483
13 May 2019 //
FDA
Aurobindo Pharma Limited Unit 16 Receives FDA Form 483
09 Apr 2019 //
FDA
Aurobindo Pharma on Health Canada Inspection List
04 Apr 2019 //
HEALTH CANADA
Enforcement Report - Week of March 27, 2019
27 Mar 2019 //
FDA
Aurobindo Pharma Limited - Unit IV Receives FDA Form 483
26 Feb 2019 //
FDA
Enforcement Report - Week of January 23, 2019
23 Jan 2019 //
FDA
Update on the review of CEP applications for sartans (18 Jan 2019)
18 Jan 2019 //
EDQM
Enforcement Report - Week of December 12, 2018
12 Dec 2018 //
FDA
FDA warns API manufacturer involved in valsartan recall
12 Dec 2018 //
FDA
Enforcement Report - Week of December 5, 2018
05 Dec 2018 //
FDA
Enforcement Report - Week of November 7, 2018
07 Nov 2018 //
FDA
Sciegen Pharmaceuticals Recalls Irbesartan Due to Trace Amounts of NDEA
31 Oct 2018 //
FDA
Aurobindo Pharma Recalls Irbesartan due to Trace NDEA Impurity
30 Oct 2018 //
FDA
Enforcement Report - Week of May 23, 2018
23 May 2018 //
FDA
FDA Issues Form 483 to Aurobindo Pharma Unit IV
08 Mar 2018 //
FDA
